High unmet needs for cervical cancer screening among women living with HIV in six African countries: A population-based study
International Journal of STD & AIDS · 2025
DOI: 10.1177/09564624251315787 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of STD & AIDS, 2025. Verfasst von Annabelle D Alpar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health Studies, Krieger School of Arts and Sciences, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD,…. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, HIV Infections, Early Detection of Cancer, Mass Screening. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIAID NIH HHS, NIMH NIH HHS.
Abstract (Originalsprache)
Background
Cisgender women living with HIV (WLWH) are disproportionately impacted by cervical cancer. Nevertheless, disparities in uptake and implementation of cervical cancer services persist in sub-Saharan Africa, where population-level estimates of screening coverage remain scarce.
Methods
We pooled data from nationally representative Population-based HIV Impact Assessment (PHIA) surveys conducted in Ethiopia, Malawi, Rwanda, Tanzania, Zambia, and Zimbabwe (2015–2019). After estimating the prevalence of self-reported lifetime cervical cancer screening (overall and by country), survey-weighted multivariable log-binomial regression identified socio-demographic and clinical correlates of screening uptake among WLWH aged 25–64 years.
Results
Overall, 6933 WLWH (mean age: 39.6 years) were included in the multi-country sample. The pooled prevalence of lifetime cervical cancer screening was 18.5% (range: 8.5% [Rwanda] to 25.3% [Zambia]). Screening uptake varied by HIV clinical status, with serostatus-aware (21.3% vs 9.0%), antiretroviral therapy-experienced (22.0% vs 10.5%), and virally suppressed (22.1% vs 11.6%) WLWH, respectively, reporting significantly ( p < 0.001) higher screening rates. Screening was especially low among WLWH aged
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Public Health Studies, Krieger School of Arts and Sciences, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
- Center for Vaccine Innovation and Access, PATH, Dakar, Senegal.
- Center for Infectious Disease and Nursing Innovation, School of Nursing, Johns Hopkins University, Baltimore, MD, USA.
- Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
- Department of Health, Behavior, and Society, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
- Department of Medicine, Warren Alpert Medical School, Brown University, Providence, RI, USA.
ORCID-Profile: Joseph G Rosen
Förderung
- NIGMS NIH HHS
- NIAID NIH HHS
- NIMH NIH HHS
- CGH CDC HHS
- National Institute of Mental Health
- Johns Hopkins University Center
- Center of Biomedical Research Excellence
- U.S. Centers for Disease Control and Prevention
Zitieren
APA
Alpar, A. D., Ndiaye, C., Guillaume, D., Limaye, R. J., & Rosen, J. G. (2025). High unmet needs for cervical cancer screening among women living with HIV in six African countries: A population-based study. International Journal of STD & AIDS. https://doi.org/10.1177/09564624251315787
Vancouver
Alpar AD, Ndiaye C, Guillaume D, Limaye RJ, Rosen JG. High unmet needs for cervical cancer screening among women living with HIV in six African countries: A population-based study. International Journal of STD & AIDS. 2025. doi:10.1177/09564624251315787
BibTeX
@article{Alpar2025,
author = {Alpar, Annabelle D and Ndiaye, Cathy and Guillaume, Dominique and Limaye, Rupali J and Rosen, Joseph G},
title = {High unmet needs for cervical cancer screening among women living with HIV in six African countries: A population-based study},
journal = {International Journal of STD & AIDS},
year = {2025},
doi = {10.1177/09564624251315787}
}
EUVIMED